Ruthenium complexes for breast cancer therapy-Reference-Cited by-同舟云学术

Ruthenium complexes for breast cancer therapy

Published:2023-07-28 Issue:0 Volume:0 Page:
ISSN:0193-4929
Container-title:Reviews in Inorganic Chemistry
language:en
Short-container-title:

Author:

Sadique Shaheen¹,Baqer Abeer Ameen²,Salman Abbas Washeel³⁴⁵,Iqbal Muhammad Adnan¹⁶^ORCID,Kadim Mustafa M.⁷⁸,Jamil Faisal¹,Majeed Adnan¹,Manahil Shaista¹,Altaf Areeba¹

Affiliation:

1. Department of Chemistry , University of Agriculture Faisalabad , Faisalabad , Pakistan

2. Medical Laboratory Techniques Department , Dijlah University College , Baghdad , Iraq

3. Department of Production , College of Agriculture, Wasit University , Kut , Iraq

4. Medical Laboratory, Techniques Department , Al-Turath University College , Baghdad , Iraq

5. College of Technical Engineering , The Islamic University , Najaf , Iraq

6. Organometallic and Coordination Chemistry, Department of Chemistry , University of Agriculture Faisalabad , Faisalabad , Pakistan

7. Medical Laboratory Techniques Department , Al-Farahidi University , Baghdad , Iraq

8. Medical Instruments Engineering Techniques , National University of Science and Technology , Thi Qar , Iraq

Abstract

Abstract Breast cancer cells have long been inhibited by polypyridine Ru(II) complexes, which are excellent antitumor agents. Due to their multi-targeting properties, this class of ruthenium complexes has received increasing attention as anticancer drug candidates approach to various cellular targets. The aim of this review is to give information about the ligands that were carefully chosen for ruthenium complexes. There has been a great deal of interest in using ruthenium-based complexes to treat breast cancer. Several species have shown potential as treatment candidates. However, further research is needed to determine how these agents affect the metastatic potential of breast cancer cells. The mechanism of action of Ru-based anticancer candidates NAMI-A and KP1019 during phase I clinical trials has been discussed. This article explains hormone-positive breast cancer and triple-negative breast-cancer treatment by using Ru complexes. Although platinum (Pt-based) anticancer medication is widely used in cancer treatment, a minor improvement has been seen and that is Platinum replaced with Ruthenium for its anticancer properties. We have also highlighted the best effective ruthenium-based complexes in treating T.N.B.C. (triple-negative breast cancer) here in this collection.

Funder

Pakistan Academy of Sciences

Higher Education Commision, Pakistan

Publisher

Walter de Gruyter GmbH

Subject

Inorganic Chemistry

Link

https://www.degruyter.com/document/doi/10.1515/revic-2023-0010/pdf

Reference110 articles.

1. Abbasi, M.; Yaqoob, M.; Haque, R. A.; Iqbal, M. A. Potential of gold candidates against human colon cancer. Mini Rev. Med. Chem. 2021, 21(1), 69–78; https://doi.org/10.2174/1389557520666200807130721.

2. Al Nasr, I. S.; Koko, W. S.; Khan, T. A.; Gürbüz, N.; Özdemir, I.; Hamdi, N. Evaluation of ruthenium (II) N-heterocyclic carbene complexes as enzymatic inhibitory agents with antioxidant, antimicrobial, antiparasitical and antiproliferative activity. Molecules 2023, 28(3), 1359; https://doi.org/10.3390/molecules28031359.

3. Alessio, E. Thirty years of the drug candidate NAMI‐A and the myths in the field of ruthenium anticancer compounds: a personal perspective. Eur. J. Inorg. Chem. 2017, 2017(12), 1549–1560; https://doi.org/10.1002/ejic.201600986.

4. Alessio, E.; Messori, L. NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: a case story in medicinal inorganic chemistry. Molecules 2019, 24(10), 1995; https://doi.org/10.3390/molecules24101995.

5. Ashraf, R.; Sarfraz, A.; Taskin-Tok, T.; Iqbal, M. J.; Iqbal, M. A.; Iqbal, J.; Bhatti, H. N.; El-Naggar, M.; Akram, S.; Murshed, M. N.; El Sayed, M. E.; Samir, A. Synthesis, molecular docking and anticancer potential of azolium based salts and their silver complexes: DNA/BSA interaction studies and cell cycle analysis. J. Mol. Liq. 2023, 369, 120921; https://doi.org/10.1016/j.molliq.2022.120921.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections;Pharmaceuticals;2023-12-15

2. Biological potential of vinyl/allyl substituted imidazole-based N-heterocyclic carbene adducts: synthesis, spectral and X-ray crystallographic structural characteristics;Chemical Papers;2023-10-19